Skip to content
DataLookout
Menu

NCT06930755

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

StatusTerminated
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: The decision about study closure has not been based on safety profile or clinical data of NMS-03305293 but a strategic decision driven by changes in the treatment landscape and anticipated significant delays in patient enrollment. Show 5 more changesShow less
    • Final enrollment: 1 participants, 4% of the 24 planned
    • Eligibility criteria expanded, about 30 words
    • Trial sites reduced: 5 → 1 locations
    • Primary completion date changed from estimate of May 31, 2027 to Aug 17, 2026
    • Secondary endpoints: details revised at 1 of 5 entries
  2. Notable Eligibility criteria expanded, about 13 words
    • Start date changed from estimate of Apr 30, 2026 to May 13, 2026
    • Secondary endpoints: details revised at 1 of 5 entries
    v9
  3. Notable Start date: Jan 31, 2026 to Apr 30, 2026v8
  4. Minor Study sites: 3 to 5v7
  5. Notable Start date: Dec 31, 2025 to Jan 31, 2026
    • Study sites: 1 to 3
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Notable Start date: Oct 30, 2025 to Dec 31, 2025v5
  2. Notable Start date: Sep 15, 2025 to Oct 30, 2025
    • Eligibility criteria expanded, about 24 words
    • Secondary endpoints revised (5)
    v4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Aug 1, 2025 to Sep 15, 2025
    • Study sites: 0 to 1
    v3
  4. Notable Primary completion date: Sep 30, 2026 to May 31, 2027
    • Start date: Jun 28, 2025 to Aug 1, 2025
    • Study completion date: Mar 30, 2027 to Sep 26, 2027
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants with Adverse Events (AEs)
Timeframe: Screening (Day ≤28) up to 28-day follow-up after end of treatment (Approximately 6 months)

Secondary (5)

Overall Response Rate (ORR)
Duration of response (DoR)
Progression-free survival (PFS)
Overall survival (OS)
Plasma pharmacokinetic profile of NMS-03305293 and possible identified metabolites (if appropriate) after oral administration

Arms and interventions

NMS-03305293 and TopotecanExperimental

NMS-03305293 will be administered orally, twice daily, on a 1-7-day schedule, in repeated 4-week cycles (i.e., 28 days). Topotecan will be administered intravenously (IV), once weekly, on Days 1, 8, and 15, of Weeks 1-3, in repeated 4-week cycles (i.e., 28 days) at 4 mg/m\^2 with maximum dose of 4 mg.

Drugs: NMS-03305293, Topotecan

Sites

1 site in 1 country

  • Penn Medicine - Perelman Center for Advanced MedicinePhiladelphia, Pennsylvania, United States